An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

A new study suggests Paxlovid may not reduce the risk of covid-19 hospitalizations and all-cause deaths in vaccinated adults ...

Studies showed that Paxlovid, a combination of two different pills — nirmatrelvir and ritonavir — reduced the risk of hospitalization and death by 88 percent. ‘Quickest way’ A patient with ...

Well, Paxlovid is a pill that you take by mouth ... Again, it's an oral pill. You take three pills a day, twice a day for five days, a total of 30 pills. It's actually two separate medications ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research. The study questions the assumption that Paxlovid's ...

THURSDAY, March 6, 2025 (HealthDay News) -- The antiviral drug Paxlovid may not offer much protection against COVID-related hospitalizations or deaths for vaccinated older adults after all.

Treatment with Paxlovid in older adults did not appear to make a difference in whether or not they were hospitalized because of COVID-19. Over a 9-month time span starting in April 2022 ...

Please provide your email address to receive an email when new articles are posted on . Paxlovid may not decrease the risk for hospitalization or death among older adults who are vaccinated.